NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1

NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1

No trades
See on Supercharts

Key facts today


Novo Nordisk's market share in the anti-obesity sector has dropped due to production issues and Wegovy shortages, allowing competitors like Eli Lilly to gain ground with better treatments.
Novo Nordisk's CagriSema, an amylin analog with GLP-1, showed disappointing Phase 3 trial results, achieving 20.4% weight loss, below the 25% target, impacting NOVO_B stock.
Novo Nordisk is testing semaglutide, its GLP-1 drug, for Alzheimer's treatment, with the main trial phase set to finish in September 2025.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪304.29 B‬USD
‪14.65 B‬USD
‪42.12 B‬USD
‪3.37 B‬
Beta (1Y)
0.93

About NOVO NORDISK B A/S


CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Founded
1931
FIGI
BBG00JVRG3N5
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
NOVO NO.F.NL 25/37 MTN
Yield to maturity
3.58%
Maturity date
May 27, 2037
N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.30%
Maturity date
May 21, 2034
N
XS300255353
NOVO NO.F.NL 25/33 MTN
Yield to maturity
3.22%
Maturity date
May 27, 2033
N
XS300255329
NOVO NO.F.NL 25/30 MTN
Yield to maturity
2.94%
Maturity date
Aug 27, 2030
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.88%
Maturity date
Jan 21, 2031
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.76%
Maturity date
Mar 31, 2030
N
XS300255299
NOVO NO.F.NL 25/28 MTN
Yield to maturity
2.59%
Maturity date
May 27, 2028
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.57%
Maturity date
Jan 21, 2029
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.56%
Maturity date
Jun 4, 2028
N
XS300255213
NOVO NO.F.NL 25/27 FLRMTN
Yield to maturity
2.48%
Maturity date
May 27, 2027
N
XS282044994
NOVO NO.F.NL 24/26 MTN
Yield to maturity
2.42%
Maturity date
May 21, 2026

See all 0TDD bonds 


Check out other big names from the same industry as 0TDD.